DeepMed Research

FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Sarcoma

Interventions: Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-09-05

Last Posted Date: 2021-05-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 37

Registration Number: NCT02888665

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: EBV-Positive Neoplastic Cells Present
HLA-A*0201 Positive Cells Present
Elevated WT1
Acute Myeloid Leukemia
Blasts Under 5 Percent of Bone Marrow Nucleated Cells

Interventions: Biological: Aldesleukin
Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-05-12

Last Posted Date: 2021-10-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 9

Registration Number: NCT02770820

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Web-Delivered Acceptance & Commitment Therapy for Smokers With Bipolar Disorder

Not Applicable

Completed

Conditions: Smoking
Bipolar Disorder

Interventions: Behavioral: Experimental plus Nicotine Replacement Therapy
Behavioral: Control plus Nicotine Replacement Therapy

First Posted Date: 2016-04-26

Last Posted Date: 2019-10-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 51

Registration Number: NCT02750904

Locations: 🇺🇸
Jefferson Center for Mental Health, Denver, Colorado, United States
🇺🇸
VA Central Western Massachusetts Healthcare System, Leeds, Massachusetts, United States
🇺🇸
Bedford VA Research Corp, Bedford, Massachusetts, United States

and more 1 locations

Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use

Not Applicable

Completed

Conditions: HIV Infection

Interventions: Drug: ART initiation at time of HIV diagnosis
Drug: ART at 24 weeks

First Posted Date: 2016-04-20

Last Posted Date: 2022-03-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 151

Registration Number: NCT02744040

Locations: 🇵🇪
Asociación Civil Impacta Salud y Educación, Lima, Peru

Trial of An Innovative Smartphone Intervention for Smoking Cessation

Not Applicable

Completed

Conditions: Smoking

Interventions: Behavioral: Smartphone-delivered Intervention (SmartQuit)

First Posted Date: 2016-03-31

Last Posted Date: 2021-01-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2503

Registration Number: NCT02724462

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Phase 1

Terminated

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Stage III Lung Non-Small Cell Cancer AJCC v7
Recurrent Acute Lymphoblastic Leukemia
Recurrent Mantle Cell Lymphoma
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Unresectable Lung Non-Small Cell Carcinoma
Malignant Solid Neoplasm
Metastatic Lung Non-Small Cell Carcinoma
Refractory Chronic Lymphocytic Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Biological: ROR1 CAR-specific Autologous T-Lymphocytes

First Posted Date: 2016-03-11

Last Posted Date: 2022-08-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT02706392

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
Drug: Cyclophosphamide
Biological: Durvalumab
Drug: Fludarabine

First Posted Date: 2016-03-11

Last Posted Date: 2022-08-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT02706405

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)

Not Applicable

Completed

Conditions: Insulin Resistance
Metabolic Syndrome
Obesity
Diabetes
NAFLD
Inflammation

Interventions: Other: Limited dairy diet
Other: Full-fat dairy diet
Other: Low-fat dairy diet

First Posted Date: 2016-01-26

Last Posted Date: 2019-01-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 72

Registration Number: NCT02663544

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Phase 2

Withdrawn

Conditions: Prolymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Drug: Idelalisib

First Posted Date: 2016-01-25

Last Posted Date: 2017-09-27

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT02662296

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors

Not Applicable

Completed

Conditions: Cancer Survivor
Stage IA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage 0 Breast Cancer
Stage IB Breast Cancer
Stage IIIA Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer

Interventions: Other: Computer-Assisted Cognitive Training
Other: Questionnaire Administration
Procedure: Standard Follow-Up Care

First Posted Date: 2016-01-25

Last Posted Date: 2017-12-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT02662335

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy